Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia - One-Year Data From the Global ETNA-AF Program

JI. Choi, S. Kiatchoosakun, P. Jiampo, HF. Tse, YOY. Soo, CC. Wang, CH. Lee, L. Pecen, M. Unverdorben, R. De Caterina, P. Kirchhof

. 2024 ; 6 (3) : 86-93. [pub] 20240220

Status neindexováno Jazyk angličtina Země Japonsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24005628

Background: This study reports prescribing patterns and the 1-year effectiveness and safety of edoxaban in an Asian cohort of Edoxaban Treatment in routiNe clinical prActice (ETNA)-Atrial Fibrillation (AF) patients. Methods and Results: The Global ETNA-AF program integrates prospective, observational, noninterventional regional studies, collecting data on characteristics and clinical outcomes of patients with AF receiving edoxaban for stroke prevention. Baseline characteristics, medical history, and 1-year clinical event rates were assessed in patients from South Korea, Taiwan, Hong Kong, and Thailand. Clinically relevant events assessed at 12 months included all-cause death, cardiovascular death, ischemic and hemorrhagic stroke, systemic embolic events (SEEs), bleeding, and net clinical outcome (NCO). Overall, 3,359 patients treated with edoxaban 60 or 30 mg once daily completed 1-year follow-up; 70.9% of patients received recommended dosing according to local labels. Baseline mean±standard deviation age was 71.7±9.6 years, CHA2DS2-VASc score was 3.1±1.5, and modified HAS-BLED score was 2.3±1.1. Mean age and sex were similar across countries/regions. The 1-year event rate for all-cause death was 1.8%; major bleeding, 1.3%; ischemic stroke, 1.1%; cardiovascular mortality, 0.7%; hemorrhagic stroke, 0.3%; SEEs, 0%; and NCO, 4.1%; with differences observed between countries/regions and dosing groups. Conclusions: Most Asian patients with AF were prescribed recommended edoxaban dosing in routine care settings. At 1-year follow-up, this analysis supports the effectiveness and safety of edoxaban in these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005628
003      
CZ-PrNML
005      
20240412130935.0
007      
ta
008      
240405s2024 ja f 000 0|eng||
009      
AR
024    7_
$a 10.1253/circrep.CR-23-0098 $2 doi
035    __
$a (PubMed)38464984
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ja
100    1_
$a Choi, Jong-Il $u Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine and Korea University Medical Center Seoul Republic of Korea
245    10
$a Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia - One-Year Data From the Global ETNA-AF Program / $c JI. Choi, S. Kiatchoosakun, P. Jiampo, HF. Tse, YOY. Soo, CC. Wang, CH. Lee, L. Pecen, M. Unverdorben, R. De Caterina, P. Kirchhof
520    9_
$a Background: This study reports prescribing patterns and the 1-year effectiveness and safety of edoxaban in an Asian cohort of Edoxaban Treatment in routiNe clinical prActice (ETNA)-Atrial Fibrillation (AF) patients. Methods and Results: The Global ETNA-AF program integrates prospective, observational, noninterventional regional studies, collecting data on characteristics and clinical outcomes of patients with AF receiving edoxaban for stroke prevention. Baseline characteristics, medical history, and 1-year clinical event rates were assessed in patients from South Korea, Taiwan, Hong Kong, and Thailand. Clinically relevant events assessed at 12 months included all-cause death, cardiovascular death, ischemic and hemorrhagic stroke, systemic embolic events (SEEs), bleeding, and net clinical outcome (NCO). Overall, 3,359 patients treated with edoxaban 60 or 30 mg once daily completed 1-year follow-up; 70.9% of patients received recommended dosing according to local labels. Baseline mean±standard deviation age was 71.7±9.6 years, CHA2DS2-VASc score was 3.1±1.5, and modified HAS-BLED score was 2.3±1.1. Mean age and sex were similar across countries/regions. The 1-year event rate for all-cause death was 1.8%; major bleeding, 1.3%; ischemic stroke, 1.1%; cardiovascular mortality, 0.7%; hemorrhagic stroke, 0.3%; SEEs, 0%; and NCO, 4.1%; with differences observed between countries/regions and dosing groups. Conclusions: Most Asian patients with AF were prescribed recommended edoxaban dosing in routine care settings. At 1-year follow-up, this analysis supports the effectiveness and safety of edoxaban in these patients.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kiatchoosakun, Songsak $u Division of Cardiology, Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University Khon Kaen Thailand
700    1_
$a Jiampo, Panyapat $u Department of Medicine, Bhumibol Adulyadej Hospital Bangkok Thailand
700    1_
$a Tse, Hung Fat $u Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong Hong Kong
700    1_
$a Soo, Yannie Oi Yan $u Division of Neurology, Department of Medicine and Therapeutics, The Faculty of Medicine, The Chinese University of Hong Kong Hong Kong
700    1_
$a Wang, Chun-Chieh $u Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou and Chang Gung University Taoyuan Taiwan
700    1_
$a Lee, Chang Hoon $u Veterans Health Service Medical Center Seoul Republic of Korea
700    1_
$a Pecen, Ladislav $u Institute of Computer Science of Academy of Sciences of the Czech Republic Prague Czech Republic
700    1_
$a Unverdorben, Martin $u Daiichi Sankyo, Inc. Basking Ridge, NJ USA
700    1_
$a De Caterina, Raffaele $u University of Pisa and Pisa University Hospital Pisa Italy
700    1_
$a Kirchhof, Paulus $u Institute of Cardiovascular Sciences, University of Birmingham Birmingham UK $u Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf Hamburg Germany $u German Center for Cardiovascular Sciences (DZHK), Partner Site Hamburg/Kiel/Lübeck Hamburg Germany
773    0_
$w MED00214679 $t Circulation reports $x 2434-0790 $g Roč. 6, č. 3 (2024), s. 86-93
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38464984 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130928 $b ABA008
999    __
$a ok $b bmc $g 2075974 $s 1215390
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 6 $c 3 $d 86-93 $e 20240220 $i 2434-0790 $m Circulation reports $n Circ Rep $x MED00214679
LZP    __
$a Pubmed-20240405

Najít záznam

Citační ukazatele

Možnosti archivace